top of page

NEWS & INSIGHTS

Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Funding Activity May 6th - 10th 2024

New companies funded and major funding events…


Want to get this list of recently funded companies and more data? Fill out a quote request to get more info or set up a call (Quote Request Form)



FIG. 1. Recent Biotech Funding Activity.



Private Funding –


Zenas BioPharma

💸  Raised $200M in series C financing led by various investors to advance obexelimab development.


Bluejay Therapeutics

💸  Secured $182M in Series C co-led by Frazier Life Sciences to accelerate development of BJT-778.


Attovia Therapeutics

💸  Raised $105m in Series B financing led by Goldman Sachs Alternatives to advance its lead programs and expand the pipeline. 


Aardvark Therapeutics

💸  Completed $85M in series C funding led by Decheng Capital to advance the development of ARD-101. 


Commit Biologics

💸  Launched with €16M seed financing led by Bioqube Ventures and Novo Holdings to develop its BiCE platform to treat cancer and autoimmune disease.



Post-IPO/Public Funding –


Organon & Co.

🏦  $1B senior notes offered for secured and unsecured funding rounds at $500M each.


Verona Pharma

🏦  Announced $650M strategic financing with Oaktree and OMERS.


Pacira BioSciences, Inc.

🏦  $250M convertible senior notes offering priced at $39.56/share.


ITeos Therapeutics

🏦  Announced $120M direct offering led by RA Capital Management and Boxer Capital to extend cash runway and to initiate a Ph 3 clinical trial by 2027.


Plus Therapeutics

🏦  To raise $18M private placement w/ participation by AIGH Capital Management LLC to fund the Re-SPECT LM program.



---


Article History:

RF, DV, DG (05/14/24)


This article is not investment or legal advice.


Comments


bottom of page